Loading...

PE anti-mouse CD279 (PD-1) Antibody PE anti-mouse CD279 (PD-1) Antibody

Pricing & Availability
Clone
29F.1A12 (See other available formats)
Regulatory Status
RUO
Other Names
PD-1, Programmed Death-1, PDCD1
Isotype
Rat IgG2a, κ
Ave. Rating
Submit a Review
Product Citations
publications
A_29F.1A12_PE_100909
Con-A and IL-2 stimulated (3 days) C57BL/6 splenocytes stained with 29F.1A12 PE and CD3 (145-2C11) APC
  • A_29F.1A12_PE_100909
    Con-A and IL-2 stimulated (3 days) C57BL/6 splenocytes stained with 29F.1A12 PE and CD3 (145-2C11) APC
  • B_29F.1A12_PE_100909
    Con A stimulated (3 days) C57BL/6 splenocytes stained with rat IgG2a isotype PE and CD3e (145-2C11) APC
Compare all formats See PE spectral data
Cat # Size Price Quantity Check Availability Save
135206 200 µg NOK2558
Check Availability


Need larger quantities of this item?
Request Bulk Quote
135205 50 µg NOK982
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

CD279, also known as programmed death-1 (PD-1), is a 50-55 kD glycoprotein belonging to the CD28 family of the Ig superfamily. PD-1 is expressed on activated splenic T and B cells and thymocytes. It is induced on activated myeloid cells as well. PD-1 is involved in lymphocyte clonal selection and peripheral tolerance through binding its ligands, B7-H1 (PD-L1) and B7-DC (PD-L2). It has been reported that PD-1 and PD-L1 interactions are critical to positive selection and play a role in shaping the T cell repertoire. PD-L1 negative costimulation is essential for prolonged survival of intratesticular islet allografts.

Product Details
Technical Data Sheet (pdf)

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Rat
Immunogen
PD-1 cDNA followed by PD-1-Ig fusion protein
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography, and conjugated with PE under optimal conditions.
Concentration
0.2 mg/ml
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤1.0 µg per million cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

Excitation Laser
Blue Laser (488 nm)
Green Laser (532 nm)/Yellow-Green Laser (561 nm)
Application Notes

Additional reported applications (for the relevant formats) include: immunohistochemical staining of acetone-fixed frozen tissue3, in vivo blocking of PD-1 binding to its ligands2,3, and spatial biology (IBEX)5,6.

Application References
  1. Good-Jacobson KL, et al. 2010. Nat. Immunol. 11:535. (FC) PubMed
  2. Lázár-Molnár E, et al. 2008. Proc. Natl. Acad. Sci. USA 105:2658. (Block)
  3. Liang SC, et al. 2003. Eur. J. Immunol. 33:2706. (FC, IHC, Block)
  4. Tobias J, et al. 2020. Front Immunol. 11:895 (FC, ELISA) PubMed
  5. Radtke AJ, et al. 2020. Proc Natl Acad Sci U S A. 117:33455-65. (SB) PubMed
  6. Radtke AJ, et al. 2022. Nat Protoc. 17:378-401. (SB) PubMed
Product Citations
  1. Dong MB, et al. 2020. Cell. 178(5):1189-1204.e23.. PubMed
  2. Spitsin S, et al. 2012. Clin Vaccine Immunol. 1.313888889. PubMed
  3. Wu Z, et al. 2023. EMBO Rep. 24:e56524. PubMed
  4. Hamdan F, et al. 2023. Mol Ther Oncolytics. 28:264. PubMed
  5. Florian DC, et al. 2023. Cancer Res Commun. 3:223. PubMed
  6. Gao Y, et al. 2023. iScience. 26:106729. PubMed
  7. Nishi W, et al. 2023. Nat Commun. 14:3157. PubMed
  8. Yang QC, et al. 2023. iScience. 26:106916. PubMed
  9. Xue G, et al. 2021. Cancer Cell. 39:1610. PubMed
  10. Serra M, et al. 2022. Cell Mol Gastroenterol Hepatol. 14:609. PubMed
  11. Liu M, et al. 2022. Cells. 11: . PubMed
  12. Wei M, et al. 2022. Front Immunol. 13:1017574. PubMed
  13. Zhao X, et al. 2022. STAR Protoc. 3:101859. PubMed
  14. Domingos-Pereira S, et al. 2022. Int J Mol Sci. 24: . PubMed
  15. Wei J, et al. 2022. Cancer Prev Res (Phila). 15:285. PubMed
  16. Wight AE, et al. 2022. Proc Natl Acad Sci U S A. 119:e2200757119. PubMed
  17. Harsha Krovi S, et al. 2020. Nat Commun. 4.790277778. PubMed
  18. Lin YN, et al. 2022. Oncoimmunology. 11:2027136. PubMed
  19. Zhang R, et al. 2021. Cell Mol Immunol. 18:1222. PubMed
  20. Hamilton JAG, et al. 2021. Aging Cell. 20:e13309. PubMed
  21. Renrick AN, et al. 2021. Front Immunol. 607044:12. PubMed
  22. Kaczanowska S, et al. 2021. Cell. 184(8):2033-2052.e21. PubMed
  23. Kim CJ, et al. 2018. Immunity. 49:1034. PubMed
  24. Sasse C, et al. 2022. Pathogens. 11:. PubMed
  25. Stolp B, et al. 2022. Cell Rep. 38:110387. PubMed
  26. Feizi N, et al. 2021. Cell Death Dis. 12:1026. PubMed
  27. Delacher M, et al. 2021. Immunity. 54(4):702-720.e17. PubMed
  28. Misumi I et al. 2019. Cell Rep. 27(2):514-524 . PubMed
  29. Kummer MP, et al. 2021. EMBO J. 40:e108662. PubMed
  30. Cai B, et al. 2021. Mol Cancer. 20:165. PubMed
  31. Kramer KJ, et al. 2022. Nat Commun. 13:3466. PubMed
  32. Lu SX, et al. 2021. Cell. . PubMed
  33. Lv H, et al. 2020. Cell Metabolism. 33(1):110-127.e5. PubMed
  34. Russell SL, et al. 2019. Cell Rep. 29:3564. PubMed
  35. Jing L, et al. 2022. Front Immunol. 13:864995. PubMed
  36. Wang Z, et al. 2021. J Virol. 95:e0141421. PubMed
  37. Zhang X, et al. 2021. Front Immunol. 12:680068. PubMed
  38. Gary EN, et al. 2021. iScience. 24(7):102699. PubMed
  39. Hu J, et al. 2020. Biomed Pharmacother. 127:110229. PubMed
  40. Liu J, et al. 2019. J Exp Med. 216:656. PubMed
  41. Wang GZ, et al. 2019. Nat Commun. 10:1125. PubMed
  42. Zhang P, et al. 2022. BMC Med. 20:435. PubMed
  43. Domeier P, et al. 2016. J Exp Med. 213: 715 - 732. PubMed
  44. Soni C, et al. 2014. J Immunol. 193:4400. PubMed
  45. Mintz MA, et al. 2019. Immunity. 51:310. PubMed
  46. Ekeke CN, et al. 2020. J Thorac Cardiovasc Surg. S0022-5223:33337. PubMed
  47. Garo LP, et al. 2019. Cell Rep. 28:3353. PubMed
  48. Fortner K, et al. 2017. Journal of Autoimmunity. 10.1016/j.jaut.2017.05.003. PubMed
  49. Wei W, et al. 2022. mSystems. 7:e0046922. PubMed
  50. Zuo S, et al. 2021. J Immunother Cancer. 9:. PubMed
  51. Reinfeld BI, et al. 2021. Nature. 593:282. PubMed
  52. Zhang YN, et al. 2020. EBioMedicine. 56:102819. PubMed
  53. LaFleur MW, et al. 2019. Nat Commun. 10:1668. PubMed
  54. Mittal A, et al. 2021. Sci Rep. 11:10731. PubMed
  55. Soni C, et al. 2020. Immunity. 52(6):1022-1038.e7. PubMed
  56. Pham D, et al. 2019. Cell Rep. 29:1203. PubMed
  57. Beloor J et al. 2018. Cell host & microbe. 23(4):549-556 . PubMed
  58. Schell S, et al. 2017. J Immunol. 10.4049/jimmunol.1700611. PubMed
  59. Zhang X, et al. 2020. Endocr Relat Cancer. 27:469. PubMed
  60. Chen C, et al. 2021. J Virol. 95:e0082921. PubMed
  61. Gomez S, et al. 2022. J Immunother Cancer. 10:. PubMed
  62. Zhang C, et al. 2021. J Immunother Cancer. 9:. PubMed
  63. Zhao X, et al. 2022. iScience. 25:104690. PubMed
  64. Moufarrij S, et al. 2020. Sci Rep. 10:3470. PubMed
  65. Liu Y, et al. 2018. Cancer Cell. 33:480. PubMed
  66. Fang W, et al. 2021. J Exp Clin Cancer Res. 40:4. PubMed
  67. Wagner AK, et al. 2022. iScience. 25:105137. PubMed
  68. Wong E, et al. 2015. J Immunol. 194:4130. PubMed
  69. Huang WC, et al. 2020. Adv Mater. 32:e2005637. PubMed
  70. Lu Y, et al. 2018. Cancer Cell. 33:1048. PubMed
  71. Zhang Z, et al. 2022. J Inflamm Res. 15:5595. PubMed
  72. Hamdan F, et al. 2021. Journal for ImmunoTherapy of Cancer. 9(8):. PubMed
  73. Roberto MP, et al. 2021. Immunity. 54(8):1807-1824.e14. PubMed
  74. Fusciello M, et al. 2019. Nat Commun. 4.407638889. PubMed
  75. Li X, et al. 2021. Front Immunol. 12:779560. PubMed
  76. Dong MB, et al. 2020. Cell. 178(5):1189-1204.e23.. PubMed
  77. Spitsin S, et al. 2012. Clin Vaccine Immunol. 1.313888889. PubMed
  78. Wu Z, et al. 2023. EMBO Rep. 24:e56524. PubMed
  79. Hamdan F, et al. 2023. Mol Ther Oncolytics. 28:264. PubMed
  80. Florian DC, et al. 2023. Cancer Res Commun. 3:223. PubMed
  81. Gao Y, et al. 2023. iScience. 26:106729. PubMed
  82. Nishi W, et al. 2023. Nat Commun. 14:3157. PubMed
  83. Yang QC, et al. 2023. iScience. 26:106916. PubMed
  84. Xue G, et al. 2021. Cancer Cell. 39:1610. PubMed
  85. Serra M, et al. 2022. Cell Mol Gastroenterol Hepatol. 14:609. PubMed
  86. Liu M, et al. 2022. Cells. 11: . PubMed
  87. Wei M, et al. 2022. Front Immunol. 13:1017574. PubMed
  88. Zhao X, et al. 2022. STAR Protoc. 3:101859. PubMed
  89. Domingos-Pereira S, et al. 2022. Int J Mol Sci. 24: . PubMed
  90. Wei J, et al. 2022. Cancer Prev Res (Phila). 15:285. PubMed
  91. Wight AE, et al. 2022. Proc Natl Acad Sci U S A. 119:e2200757119. PubMed
  92. Harsha Krovi S, et al. 2020. Nat Commun. 4.790277778. PubMed
  93. Lin YN, et al. 2022. Oncoimmunology. 11:2027136. PubMed
  94. Zhang R, et al. 2021. Cell Mol Immunol. 18:1222. PubMed
  95. Hamilton JAG, et al. 2021. Aging Cell. 20:e13309. PubMed
  96. Renrick AN, et al. 2021. Front Immunol. 607044:12. PubMed
  97. Kaczanowska S, et al. 2021. Cell. 184(8):2033-2052.e21. PubMed
  98. Kim CJ, et al. 2018. Immunity. 49:1034. PubMed
  99. Sasse C, et al. 2022. Pathogens. 11:. PubMed
  100. Stolp B, et al. 2022. Cell Rep. 38:110387. PubMed
  101. Feizi N, et al. 2021. Cell Death Dis. 12:1026. PubMed
  102. Delacher M, et al. 2021. Immunity. 54(4):702-720.e17. PubMed
  103. Misumi I et al. 2019. Cell Rep. 27(2):514-524 . PubMed
  104. Kummer MP, et al. 2021. EMBO J. 40:e108662. PubMed
  105. Cai B, et al. 2021. Mol Cancer. 20:165. PubMed
  106. Kramer KJ, et al. 2022. Nat Commun. 13:3466. PubMed
  107. Lu SX, et al. 2021. Cell. . PubMed
  108. Lv H, et al. 2020. Cell Metabolism. 33(1):110-127.e5. PubMed
  109. Russell SL, et al. 2019. Cell Rep. 29:3564. PubMed
  110. Jing L, et al. 2022. Front Immunol. 13:864995. PubMed
  111. Wang Z, et al. 2021. J Virol. 95:e0141421. PubMed
  112. Zhang X, et al. 2021. Front Immunol. 12:680068. PubMed
  113. Gary EN, et al. 2021. iScience. 24(7):102699. PubMed
  114. Hu J, et al. 2020. Biomed Pharmacother. 127:110229. PubMed
  115. Liu J, et al. 2019. J Exp Med. 216:656. PubMed
  116. Wang GZ, et al. 2019. Nat Commun. 10:1125. PubMed
  117. Zhang P, et al. 2022. BMC Med. 20:435. PubMed
  118. Domeier P, et al. 2016. J Exp Med. 213: 715 - 732. PubMed
  119. Soni C, et al. 2014. J Immunol. 193:4400. PubMed
  120. Mintz MA, et al. 2019. Immunity. 51:310. PubMed
  121. Ekeke CN, et al. 2020. J Thorac Cardiovasc Surg. S0022-5223:33337. PubMed
  122. Garo LP, et al. 2019. Cell Rep. 28:3353. PubMed
  123. Fortner K, et al. 2017. Journal of Autoimmunity. 10.1016/j.jaut.2017.05.003. PubMed
  124. Wei W, et al. 2022. mSystems. 7:e0046922. PubMed
  125. Zuo S, et al. 2021. J Immunother Cancer. 9:. PubMed
  126. Reinfeld BI, et al. 2021. Nature. 593:282. PubMed
  127. Zhang YN, et al. 2020. EBioMedicine. 56:102819. PubMed
  128. LaFleur MW, et al. 2019. Nat Commun. 10:1668. PubMed
  129. Mittal A, et al. 2021. Sci Rep. 11:10731. PubMed
  130. Soni C, et al. 2020. Immunity. 52(6):1022-1038.e7. PubMed
  131. Pham D, et al. 2019. Cell Rep. 29:1203. PubMed
  132. Beloor J et al. 2018. Cell host & microbe. 23(4):549-556 . PubMed
  133. Schell S, et al. 2017. J Immunol. 10.4049/jimmunol.1700611. PubMed
  134. Zhang X, et al. 2020. Endocr Relat Cancer. 27:469. PubMed
  135. Chen C, et al. 2021. J Virol. 95:e0082921. PubMed
  136. Gomez S, et al. 2022. J Immunother Cancer. 10:. PubMed
  137. Zhang C, et al. 2021. J Immunother Cancer. 9:. PubMed
  138. Zhao X, et al. 2022. iScience. 25:104690. PubMed
  139. Moufarrij S, et al. 2020. Sci Rep. 10:3470. PubMed
  140. Liu Y, et al. 2018. Cancer Cell. 33:480. PubMed
  141. Fang W, et al. 2021. J Exp Clin Cancer Res. 40:4. PubMed
  142. Wagner AK, et al. 2022. iScience. 25:105137. PubMed
  143. Wong E, et al. 2015. J Immunol. 194:4130. PubMed
  144. Huang WC, et al. 2020. Adv Mater. 32:e2005637. PubMed
  145. Lu Y, et al. 2018. Cancer Cell. 33:1048. PubMed
  146. Zhang Z, et al. 2022. J Inflamm Res. 15:5595. PubMed
  147. Hamdan F, et al. 2021. Journal for ImmunoTherapy of Cancer. 9(8):. PubMed
  148. Roberto MP, et al. 2021. Immunity. 54(8):1807-1824.e14. PubMed
  149. Fusciello M, et al. 2019. Nat Commun. 4.407638889. PubMed
  150. Li X, et al. 2021. Front Immunol. 12:779560. PubMed
RRID
AB_1877231 (BioLegend Cat. No. 135206)
AB_1877232 (BioLegend Cat. No. 135205)

Antigen Details

Structure
A 50-55 kD glycoprotein belonging to the CD28 family of the Ig superfamily.
Distribution

Induced on splenic T and B lymphocytes, thymocytes, and myeloid cells after stimulation.

Function
Involved in lymphocyte clonal selection and peripheral tolerance, prolonged survival of allografts.
Ligand/Receptor
B7-H1 (PD-L1) and B7-DC (PD-L2)
Cell Type
B cells, T cells
Biology Area
Cancer Biomarkers, Immunology, Inhibitory Molecules
Molecular Family
CD Molecules, Immune Checkpoint Receptors
Antigen References

1. Nishimura H, et al. 2001. Science 291:319
2. Agata Y, et al. 1996. Int. Immunol. 8:765
3. Liang SC, et al. 2003. Eur. J. Immunol. 33:2706
4. Barber DL, et al. 2006. Nature 439:682
5. Keir ME, et al. 2005. J. Immunol. 175:7372
6. Koehn BH. et al. 2008. J Immunol. 181:5313

Gene ID
18566 View all products for this Gene ID
UniProt
View information about CD279 on UniProt.org

Related FAQs

What type of PE do you use in your conjugates?
We use R-PE in our conjugates.

Other Formats

View All PD-1 Reagents Request Custom Conjugation
Description Clone Applications
PE/Dazzle™ 594 anti-mouse CD279 (PD-1) 29F.1A12 FC
Alexa Fluor® 647 anti-mouse CD279 (PD-1) 29F.1A12 FC
Brilliant Violet 711™ anti-mouse CD279 (PD-1) 29F.1A12 FC
GoInVivo™ Purified anti-mouse CD279 (PD-1) 29F.1A12 FC
APC/Fire™ 750 anti-mouse CD279 (PD-1) 29F.1A12 FC
Brilliant Violet 510™ anti-mouse CD279 (PD-1) 29F.1A12 FC
Ultra-LEAF™ Purified anti-mouse CD279 (PD-1) 29F.1A12 FC,IHC-F,Block
PE anti-mouse CD279 (PD-1) 29F.1A12 FC
Purified anti-mouse CD279 (PD-1) 29F.1A12 FC,IHC-F,Block,ELISA
PerCP/Cyanine5.5 anti-mouse CD279 (PD-1) 29F.1A12 FC
APC anti-mouse CD279 (PD-1) 29F.1A12 FC
Biotin anti-mouse CD279 (PD-1) 29F.1A12 FC
FITC anti-mouse CD279 (PD-1) 29F.1A12 FC
PE/Cyanine7 anti-mouse CD279 (PD-1) 29F.1A12 FC
Brilliant Violet 421™ anti-mouse CD279 (PD-1) 29F.1A12 FC,SB
Brilliant Violet 605™ anti-mouse CD279 (PD-1) 29F.1A12 FC
APC/Cyanine7 anti-mouse CD279 (PD-1) 29F.1A12 FC
Brilliant Violet 785™ anti-mouse CD279 (PD-1) 29F.1A12 FC
APC/Fire™ 810 anti-mouse CD279 (PD-1) Antibody 29F.1A12 FC
PE/Fire™ 810 anti-mouse CD279 (PD-1) Antibody 29F.1A12 FC
PE/Cyanine5 anti-mouse CD279 (PD-1) 29F.1A12 FC
PE/Fire™ 640 anti-mouse CD279 (PD-1) 29F.1A12 FC
Spark Red™ 718 anti-mouse CD279 (PD-1) 29F.1A12 FC
PerCP/Fire™ 806 anti-mouse CD279 (PD-1) 29F.1A12 FC
Brilliant Violet 750™ anti-mouse CD279 (PD-1) 29F.1A12 FC
PerCP/Fire™ 780 anti-mouse CD279 (PD-1) 29F.1A12 FC
PE/Fire™ 700 anti-mouse CD279 (PD-1) 29F.1A12 FC
PE/Fire™ 744 anti-mouse CD279 (PD-1) 29F.1A12 FC
Brilliant Violet 650™ anti-mouse CD279 (PD-1) 29F.1A12 FC
Spark Blue™ 574 anti-mouse CD279 (PD-1) (Flexi-Fluor™) 29F.1A12 FC
Spark PLUS B550™ anti-mouse CD279 (PD-1) 29F.1A12 FC
Spark YG™ 581 anti-mouse CD279 (PD-1) (Flexi-Fluor™) 29F.1A12 FC
Spark YG™ 593 anti-mouse CD279 (PD-1) (Flexi-Fluor™) Antibody 29F.1A12 FC
Spark NIR™ 685 anti-mouse CD279 (PD-1) (Flexi-Fluor™) Antibody 29F.1A12 FC
Go To Top Version: 3    Revision Date: 09.11.2014

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

Pricing & Availability
Clone
29F.1A12 (See other available formats)
Regulatory Status
RUO
Other Names
PD-1, Programmed Death-1, PDCD1
Isotype
Rat IgG2a, κ
Ave. Rating
Submit a Review
Product Citations
publications
A_29F.1A12_PE_100909
Con-A and IL-2 stimulated (3 days) C57BL/6 splenocytes stained with 29F.1A12 PE and CD3 (145-2C11) APC
  • A_29F.1A12_PE_100909
    Con-A and IL-2 stimulated (3 days) C57BL/6 splenocytes stained with 29F.1A12 PE and CD3 (145-2C11) APC
  • B_29F.1A12_PE_100909
    Con A stimulated (3 days) C57BL/6 splenocytes stained with rat IgG2a isotype PE and CD3e (145-2C11) APC
Compare all formats See PE spectral data
Cat # Size Price Quantity Check Availability Save
135206 200 µg NOK2558
Check Availability


Need larger quantities of this item?
Request Bulk Quote
135205 50 µg NOK982
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

CD279, also known as programmed death-1 (PD-1), is a 50-55 kD glycoprotein belonging to the CD28 family of the Ig superfamily. PD-1 is expressed on activated splenic T and B cells and thymocytes. It is induced on activated myeloid cells as well. PD-1 is involved in lymphocyte clonal selection and peripheral tolerance through binding its ligands, B7-H1 (PD-L1) and B7-DC (PD-L2). It has been reported that PD-1 and PD-L1 interactions are critical to positive selection and play a role in shaping the T cell repertoire. PD-L1 negative costimulation is essential for prolonged survival of intratesticular islet allografts.

Product Details
Technical Data Sheet (pdf)

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Rat
Immunogen
PD-1 cDNA followed by PD-1-Ig fusion protein
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography, and conjugated with PE under optimal conditions.
Concentration
0.2 mg/ml
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤1.0 µg per million cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

Excitation Laser
Blue Laser (488 nm)
Green Laser (532 nm)/Yellow-Green Laser (561 nm)
Application Notes

Additional reported applications (for the relevant formats) include: immunohistochemical staining of acetone-fixed frozen tissue3, in vivo blocking of PD-1 binding to its ligands2,3, and spatial biology (IBEX)5,6.

Application References
  1. Good-Jacobson KL, et al. 2010. Nat. Immunol. 11:535. (FC) PubMed
  2. Lázár-Molnár E, et al. 2008. Proc. Natl. Acad. Sci. USA 105:2658. (Block)
  3. Liang SC, et al. 2003. Eur. J. Immunol. 33:2706. (FC, IHC, Block)
  4. Tobias J, et al. 2020. Front Immunol. 11:895 (FC, ELISA) PubMed
  5. Radtke AJ, et al. 2020. Proc Natl Acad Sci U S A. 117:33455-65. (SB) PubMed
  6. Radtke AJ, et al. 2022. Nat Protoc. 17:378-401. (SB) PubMed
Product Citations
  1. Dong MB, et al. 2020. Cell. 178(5):1189-1204.e23.. PubMed
  2. Spitsin S, et al. 2012. Clin Vaccine Immunol. 1.313888889. PubMed
  3. Wu Z, et al. 2023. EMBO Rep. 24:e56524. PubMed
  4. Hamdan F, et al. 2023. Mol Ther Oncolytics. 28:264. PubMed
  5. Florian DC, et al. 2023. Cancer Res Commun. 3:223. PubMed
  6. Gao Y, et al. 2023. iScience. 26:106729. PubMed
  7. Nishi W, et al. 2023. Nat Commun. 14:3157. PubMed
  8. Yang QC, et al. 2023. iScience. 26:106916. PubMed
  9. Xue G, et al. 2021. Cancer Cell. 39:1610. PubMed
  10. Serra M, et al. 2022. Cell Mol Gastroenterol Hepatol. 14:609. PubMed
  11. Liu M, et al. 2022. Cells. 11: . PubMed
  12. Wei M, et al. 2022. Front Immunol. 13:1017574. PubMed
  13. Zhao X, et al. 2022. STAR Protoc. 3:101859. PubMed
  14. Domingos-Pereira S, et al. 2022. Int J Mol Sci. 24: . PubMed
  15. Wei J, et al. 2022. Cancer Prev Res (Phila). 15:285. PubMed
  16. Wight AE, et al. 2022. Proc Natl Acad Sci U S A. 119:e2200757119. PubMed
  17. Harsha Krovi S, et al. 2020. Nat Commun. 4.790277778. PubMed
  18. Lin YN, et al. 2022. Oncoimmunology. 11:2027136. PubMed
  19. Zhang R, et al. 2021. Cell Mol Immunol. 18:1222. PubMed
  20. Hamilton JAG, et al. 2021. Aging Cell. 20:e13309. PubMed
  21. Renrick AN, et al. 2021. Front Immunol. 607044:12. PubMed
  22. Kaczanowska S, et al. 2021. Cell. 184(8):2033-2052.e21. PubMed
  23. Kim CJ, et al. 2018. Immunity. 49:1034. PubMed
  24. Sasse C, et al. 2022. Pathogens. 11:. PubMed
  25. Stolp B, et al. 2022. Cell Rep. 38:110387. PubMed
  26. Feizi N, et al. 2021. Cell Death Dis. 12:1026. PubMed
  27. Delacher M, et al. 2021. Immunity. 54(4):702-720.e17. PubMed
  28. Misumi I et al. 2019. Cell Rep. 27(2):514-524 . PubMed
  29. Kummer MP, et al. 2021. EMBO J. 40:e108662. PubMed
  30. Cai B, et al. 2021. Mol Cancer. 20:165. PubMed
  31. Kramer KJ, et al. 2022. Nat Commun. 13:3466. PubMed
  32. Lu SX, et al. 2021. Cell. . PubMed
  33. Lv H, et al. 2020. Cell Metabolism. 33(1):110-127.e5. PubMed
  34. Russell SL, et al. 2019. Cell Rep. 29:3564. PubMed
  35. Jing L, et al. 2022. Front Immunol. 13:864995. PubMed
  36. Wang Z, et al. 2021. J Virol. 95:e0141421. PubMed
  37. Zhang X, et al. 2021. Front Immunol. 12:680068. PubMed
  38. Gary EN, et al. 2021. iScience. 24(7):102699. PubMed
  39. Hu J, et al. 2020. Biomed Pharmacother. 127:110229. PubMed
  40. Liu J, et al. 2019. J Exp Med. 216:656. PubMed
  41. Wang GZ, et al. 2019. Nat Commun. 10:1125. PubMed
  42. Zhang P, et al. 2022. BMC Med. 20:435. PubMed
  43. Domeier P, et al. 2016. J Exp Med. 213: 715 - 732. PubMed
  44. Soni C, et al. 2014. J Immunol. 193:4400. PubMed
  45. Mintz MA, et al. 2019. Immunity. 51:310. PubMed
  46. Ekeke CN, et al. 2020. J Thorac Cardiovasc Surg. S0022-5223:33337. PubMed
  47. Garo LP, et al. 2019. Cell Rep. 28:3353. PubMed
  48. Fortner K, et al. 2017. Journal of Autoimmunity. 10.1016/j.jaut.2017.05.003. PubMed
  49. Wei W, et al. 2022. mSystems. 7:e0046922. PubMed
  50. Zuo S, et al. 2021. J Immunother Cancer. 9:. PubMed
  51. Reinfeld BI, et al. 2021. Nature. 593:282. PubMed
  52. Zhang YN, et al. 2020. EBioMedicine. 56:102819. PubMed
  53. LaFleur MW, et al. 2019. Nat Commun. 10:1668. PubMed
  54. Mittal A, et al. 2021. Sci Rep. 11:10731. PubMed
  55. Soni C, et al. 2020. Immunity. 52(6):1022-1038.e7. PubMed
  56. Pham D, et al. 2019. Cell Rep. 29:1203. PubMed
  57. Beloor J et al. 2018. Cell host & microbe. 23(4):549-556 . PubMed
  58. Schell S, et al. 2017. J Immunol. 10.4049/jimmunol.1700611. PubMed
  59. Zhang X, et al. 2020. Endocr Relat Cancer. 27:469. PubMed
  60. Chen C, et al. 2021. J Virol. 95:e0082921. PubMed
  61. Gomez S, et al. 2022. J Immunother Cancer. 10:. PubMed
  62. Zhang C, et al. 2021. J Immunother Cancer. 9:. PubMed
  63. Zhao X, et al. 2022. iScience. 25:104690. PubMed
  64. Moufarrij S, et al. 2020. Sci Rep. 10:3470. PubMed
  65. Liu Y, et al. 2018. Cancer Cell. 33:480. PubMed
  66. Fang W, et al. 2021. J Exp Clin Cancer Res. 40:4. PubMed
  67. Wagner AK, et al. 2022. iScience. 25:105137. PubMed
  68. Wong E, et al. 2015. J Immunol. 194:4130. PubMed
  69. Huang WC, et al. 2020. Adv Mater. 32:e2005637. PubMed
  70. Lu Y, et al. 2018. Cancer Cell. 33:1048. PubMed
  71. Zhang Z, et al. 2022. J Inflamm Res. 15:5595. PubMed
  72. Hamdan F, et al. 2021. Journal for ImmunoTherapy of Cancer. 9(8):. PubMed
  73. Roberto MP, et al. 2021. Immunity. 54(8):1807-1824.e14. PubMed
  74. Fusciello M, et al. 2019. Nat Commun. 4.407638889. PubMed
  75. Li X, et al. 2021. Front Immunol. 12:779560. PubMed
  76. Dong MB, et al. 2020. Cell. 178(5):1189-1204.e23.. PubMed
  77. Spitsin S, et al. 2012. Clin Vaccine Immunol. 1.313888889. PubMed
  78. Wu Z, et al. 2023. EMBO Rep. 24:e56524. PubMed
  79. Hamdan F, et al. 2023. Mol Ther Oncolytics. 28:264. PubMed
  80. Florian DC, et al. 2023. Cancer Res Commun. 3:223. PubMed
  81. Gao Y, et al. 2023. iScience. 26:106729. PubMed
  82. Nishi W, et al. 2023. Nat Commun. 14:3157. PubMed
  83. Yang QC, et al. 2023. iScience. 26:106916. PubMed
  84. Xue G, et al. 2021. Cancer Cell. 39:1610. PubMed
  85. Serra M, et al. 2022. Cell Mol Gastroenterol Hepatol. 14:609. PubMed
  86. Liu M, et al. 2022. Cells. 11: . PubMed
  87. Wei M, et al. 2022. Front Immunol. 13:1017574. PubMed
  88. Zhao X, et al. 2022. STAR Protoc. 3:101859. PubMed
  89. Domingos-Pereira S, et al. 2022. Int J Mol Sci. 24: . PubMed
  90. Wei J, et al. 2022. Cancer Prev Res (Phila). 15:285. PubMed
  91. Wight AE, et al. 2022. Proc Natl Acad Sci U S A. 119:e2200757119. PubMed
  92. Harsha Krovi S, et al. 2020. Nat Commun. 4.790277778. PubMed
  93. Lin YN, et al. 2022. Oncoimmunology. 11:2027136. PubMed
  94. Zhang R, et al. 2021. Cell Mol Immunol. 18:1222. PubMed
  95. Hamilton JAG, et al. 2021. Aging Cell. 20:e13309. PubMed
  96. Renrick AN, et al. 2021. Front Immunol. 607044:12. PubMed
  97. Kaczanowska S, et al. 2021. Cell. 184(8):2033-2052.e21. PubMed
  98. Kim CJ, et al. 2018. Immunity. 49:1034. PubMed
  99. Sasse C, et al. 2022. Pathogens. 11:. PubMed
  100. Stolp B, et al. 2022. Cell Rep. 38:110387. PubMed
  101. Feizi N, et al. 2021. Cell Death Dis. 12:1026. PubMed
  102. Delacher M, et al. 2021. Immunity. 54(4):702-720.e17. PubMed
  103. Misumi I et al. 2019. Cell Rep. 27(2):514-524 . PubMed
  104. Kummer MP, et al. 2021. EMBO J. 40:e108662. PubMed
  105. Cai B, et al. 2021. Mol Cancer. 20:165. PubMed
  106. Kramer KJ, et al. 2022. Nat Commun. 13:3466. PubMed
  107. Lu SX, et al. 2021. Cell. . PubMed
  108. Lv H, et al. 2020. Cell Metabolism. 33(1):110-127.e5. PubMed
  109. Russell SL, et al. 2019. Cell Rep. 29:3564. PubMed
  110. Jing L, et al. 2022. Front Immunol. 13:864995. PubMed
  111. Wang Z, et al. 2021. J Virol. 95:e0141421. PubMed
  112. Zhang X, et al. 2021. Front Immunol. 12:680068. PubMed
  113. Gary EN, et al. 2021. iScience. 24(7):102699. PubMed
  114. Hu J, et al. 2020. Biomed Pharmacother. 127:110229. PubMed
  115. Liu J, et al. 2019. J Exp Med. 216:656. PubMed
  116. Wang GZ, et al. 2019. Nat Commun. 10:1125. PubMed
  117. Zhang P, et al. 2022. BMC Med. 20:435. PubMed
  118. Domeier P, et al. 2016. J Exp Med. 213: 715 - 732. PubMed
  119. Soni C, et al. 2014. J Immunol. 193:4400. PubMed
  120. Mintz MA, et al. 2019. Immunity. 51:310. PubMed
  121. Ekeke CN, et al. 2020. J Thorac Cardiovasc Surg. S0022-5223:33337. PubMed
  122. Garo LP, et al. 2019. Cell Rep. 28:3353. PubMed
  123. Fortner K, et al. 2017. Journal of Autoimmunity. 10.1016/j.jaut.2017.05.003. PubMed
  124. Wei W, et al. 2022. mSystems. 7:e0046922. PubMed
  125. Zuo S, et al. 2021. J Immunother Cancer. 9:. PubMed
  126. Reinfeld BI, et al. 2021. Nature. 593:282. PubMed
  127. Zhang YN, et al. 2020. EBioMedicine. 56:102819. PubMed
  128. LaFleur MW, et al. 2019. Nat Commun. 10:1668. PubMed
  129. Mittal A, et al. 2021. Sci Rep. 11:10731. PubMed
  130. Soni C, et al. 2020. Immunity. 52(6):1022-1038.e7. PubMed
  131. Pham D, et al. 2019. Cell Rep. 29:1203. PubMed
  132. Beloor J et al. 2018. Cell host & microbe. 23(4):549-556 . PubMed
  133. Schell S, et al. 2017. J Immunol. 10.4049/jimmunol.1700611. PubMed
  134. Zhang X, et al. 2020. Endocr Relat Cancer. 27:469. PubMed
  135. Chen C, et al. 2021. J Virol. 95:e0082921. PubMed
  136. Gomez S, et al. 2022. J Immunother Cancer. 10:. PubMed
  137. Zhang C, et al. 2021. J Immunother Cancer. 9:. PubMed
  138. Zhao X, et al. 2022. iScience. 25:104690. PubMed
  139. Moufarrij S, et al. 2020. Sci Rep. 10:3470. PubMed
  140. Liu Y, et al. 2018. Cancer Cell. 33:480. PubMed
  141. Fang W, et al. 2021. J Exp Clin Cancer Res. 40:4. PubMed
  142. Wagner AK, et al. 2022. iScience. 25:105137. PubMed
  143. Wong E, et al. 2015. J Immunol. 194:4130. PubMed
  144. Huang WC, et al. 2020. Adv Mater. 32:e2005637. PubMed
  145. Lu Y, et al. 2018. Cancer Cell. 33:1048. PubMed
  146. Zhang Z, et al. 2022. J Inflamm Res. 15:5595. PubMed
  147. Hamdan F, et al. 2021. Journal for ImmunoTherapy of Cancer. 9(8):. PubMed
  148. Roberto MP, et al. 2021. Immunity. 54(8):1807-1824.e14. PubMed
  149. Fusciello M, et al. 2019. Nat Commun. 4.407638889. PubMed
  150. Li X, et al. 2021. Front Immunol. 12:779560. PubMed
RRID
AB_1877231 (BioLegend Cat. No. 135206)
AB_1877232 (BioLegend Cat. No. 135205)

Antigen Details

Structure
A 50-55 kD glycoprotein belonging to the CD28 family of the Ig superfamily.
Distribution

Induced on splenic T and B lymphocytes, thymocytes, and myeloid cells after stimulation.

Function
Involved in lymphocyte clonal selection and peripheral tolerance, prolonged survival of allografts.
Ligand/Receptor
B7-H1 (PD-L1) and B7-DC (PD-L2)
Cell Type
B cells, T cells
Biology Area
Cancer Biomarkers, Immunology, Inhibitory Molecules
Molecular Family
CD Molecules, Immune Checkpoint Receptors
Antigen References

1. Nishimura H, et al. 2001. Science 291:319
2. Agata Y, et al. 1996. Int. Immunol. 8:765
3. Liang SC, et al. 2003. Eur. J. Immunol. 33:2706
4. Barber DL, et al. 2006. Nature 439:682
5. Keir ME, et al. 2005. J. Immunol. 175:7372
6. Koehn BH. et al. 2008. J Immunol. 181:5313

Gene ID
18566 View all products for this Gene ID
UniProt
View information about CD279 on UniProt.org

Related FAQs

What type of PE do you use in your conjugates?
We use R-PE in our conjugates.

Other Formats

View All PD-1 Reagents Request Custom Conjugation
Description Clone Applications
PE/Dazzle™ 594 anti-mouse CD279 (PD-1) 29F.1A12 FC
Alexa Fluor® 647 anti-mouse CD279 (PD-1) 29F.1A12 FC
Brilliant Violet 711™ anti-mouse CD279 (PD-1) 29F.1A12 FC
GoInVivo™ Purified anti-mouse CD279 (PD-1) 29F.1A12 FC
APC/Fire™ 750 anti-mouse CD279 (PD-1) 29F.1A12 FC
Brilliant Violet 510™ anti-mouse CD279 (PD-1) 29F.1A12 FC
Ultra-LEAF™ Purified anti-mouse CD279 (PD-1) 29F.1A12 FC,IHC-F,Block
PE anti-mouse CD279 (PD-1) 29F.1A12 FC
Purified anti-mouse CD279 (PD-1) 29F.1A12 FC,IHC-F,Block,ELISA
PerCP/Cyanine5.5 anti-mouse CD279 (PD-1) 29F.1A12 FC
APC anti-mouse CD279 (PD-1) 29F.1A12 FC
Biotin anti-mouse CD279 (PD-1) 29F.1A12 FC
FITC anti-mouse CD279 (PD-1) 29F.1A12 FC
PE/Cyanine7 anti-mouse CD279 (PD-1) 29F.1A12 FC
Brilliant Violet 421™ anti-mouse CD279 (PD-1) 29F.1A12 FC,SB
Brilliant Violet 605™ anti-mouse CD279 (PD-1) 29F.1A12 FC
APC/Cyanine7 anti-mouse CD279 (PD-1) 29F.1A12 FC
Brilliant Violet 785™ anti-mouse CD279 (PD-1) 29F.1A12 FC
APC/Fire™ 810 anti-mouse CD279 (PD-1) Antibody 29F.1A12 FC
PE/Fire™ 810 anti-mouse CD279 (PD-1) Antibody 29F.1A12 FC
PE/Cyanine5 anti-mouse CD279 (PD-1) 29F.1A12 FC
PE/Fire™ 640 anti-mouse CD279 (PD-1) 29F.1A12 FC
Spark Red™ 718 anti-mouse CD279 (PD-1) 29F.1A12 FC
PerCP/Fire™ 806 anti-mouse CD279 (PD-1) 29F.1A12 FC
Brilliant Violet 750™ anti-mouse CD279 (PD-1) 29F.1A12 FC
PerCP/Fire™ 780 anti-mouse CD279 (PD-1) 29F.1A12 FC
PE/Fire™ 700 anti-mouse CD279 (PD-1) 29F.1A12 FC
PE/Fire™ 744 anti-mouse CD279 (PD-1) 29F.1A12 FC
Brilliant Violet 650™ anti-mouse CD279 (PD-1) 29F.1A12 FC
Spark Blue™ 574 anti-mouse CD279 (PD-1) (Flexi-Fluor™) 29F.1A12 FC
Spark PLUS B550™ anti-mouse CD279 (PD-1) 29F.1A12 FC
Spark YG™ 581 anti-mouse CD279 (PD-1) (Flexi-Fluor™) 29F.1A12 FC
Spark YG™ 593 anti-mouse CD279 (PD-1) (Flexi-Fluor™) Antibody 29F.1A12 FC
Spark NIR™ 685 anti-mouse CD279 (PD-1) (Flexi-Fluor™) Antibody 29F.1A12 FC
Go To Top Version: 3    Revision Date: 09.11.2014

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account